药物基因组学检测的价值:真实世界药物利用与基因型数据评估
2年随访中60.4%全国队列患者购买至少一种可干预药物,基因型亚组98.8%携带至少一种可干预基因型。基于文献的成本效益模型显示,对大学医院患者进行无靶向先发药物基因组学检测,2年内每人可节省直接医疗系统成本17.49欧元(未计入检测成本)。
要点
- 60.4%全国队列患者在2年内购买至少一种药物基因组学可干预药物,最常见为布洛芬(25.0%)和可待因(19.4%)。
- 基因型亚组中98.8%携带至少一种可干预药物基因组学基因型,23.3%存在至少一对可干预基因-药物配对。
- 无靶向先发检测模型示每人2年节省€17.49直接医疗成本(未计检测费),提示宜靶向高风险患者群。
核心结论
- 对大学医院患者进行无靶向先发药物基因组学检测,模型显示2年内每人节省直接医疗系统成本€17.49(未计入检测成本)。
- 鉴于绝大多数患者携带可干预基因型且多数使用可干预药物,将先发检测靶向最可能使用可干预药物的患者群体可能更合理。
研究设计与样本
- 另分析2178例大学医院患者的药物购买与处方数据,其中930例有全基因组基因型数据。
- 开发基于文献的成本效益模型,评估先发药物基因组学面板检测。
主要发现
- 2年随访中,全国队列60.4%患者购买至少一种药物基因组学可干预药物,最常见为布洛芬(25.0%)和可待因(19.4%)。
- 基因型亚组中98.8%携带至少一种可干预药物基因组学基因型,23.3%存在至少一对可干预基因-药物配对。
- 肌肉骨骼或心血管疾病患者在住院期间更易接受药物基因组学可干预药物。
- 大学医院队列中常 dispensing 药物包括昂丹司琼(19.4%)、辛伐他汀(7.4%)、氯吡格雷(5.0%)、华法林(5.1%)、(艾司)西酞普兰(5.3%)和硫唑嘌呤(0.5%)。
关键数值与推荐
- 全国队列2年随访中60.4%患者购买至少一种药物基因组学可干预药物。
- 基因型亚组98.8%携带至少一种可干预基因型,23.3%有至少一对可干预基因-药物配对。
- 成本效益模型示无靶向先发检测每人2年节省€17.49直接医疗成本(未计检测费)。
临床怎么用
- 可考虑将先发药物基因组学检测靶向最可能接受可干预药物的患者群体,如肌肉骨骼或心血管疾病患者。
- 临床药师可结合患者疾病类型与用药史,识别可能从药物基因组学检测中获益的高风险人群。
局限性
- 研究为回顾性注册设计,可能存在未测量混杂。
- 成本效益模型基于文献假设,未计入检测成本,外推需谨慎。
- 基因型数据仅来自大学医院子集(n=930),代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Implementation of pharmacogenetic testing in clinical care has been slow and with few exceptions is hindered by the lack of real-world evidence on how to best target testing. In this retrospective register-based study, we analyzed a nationwide cohort of 1,425,000 patients discharged from internal medicine or surgical wards and a cohort of 2,178 university hospital patients for purchases and prescriptions of pharmacogenetically actionable drugs. Pharmacogenetic variants were obtained from whole genome genotype data for a subset (n = 930) of the university hospital patients. We investigated factors associated with receiving pharmacogenetically actionable drugs and developed a literature-based cost-benefit model for pre-emptive pharmacogenetic panel testing. In a 2-year follow-up, 60.4% of the patients in the nationwide cohort purchased at least one pharmacogenetically actionable drug, most commonly ibuprofen (25.0%) and codeine (19.4%). Of the genotyped subset, 98.8% carried at least one actionable pharmacogenetic genotype and 23.3% had at least one actionable gene-drug pair. Patients suffering from musculoskeletal or cardiovascular diseases were more prone to receive pharmacogenetically actionable drugs during inpatient episode. The cost-benefit model included frequently dispensed drugs in the university hospital cohort, comprising ondansetron (19.4%), simvastatin (7.4%), clopidogrel (5.0%), warfarin (5.1%), (es)citalopram (5.3%), and azathioprine (0.5%). For untargeted pre-emptive pharmacogenetic testing of all university hospital patients, the model indicated saving €17.49 in direct healthcare system costs per patient in 2 years without accounting for the cost of the test itself. Therefore, it might be reasonable to target pre-emptive pharmacogenetic testing to patient groups most likely to receive pharmacogenetically actionable drugs.
引用
- Litonius K, Kulla N, Falkenbach P, et al. Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data. Clin Pharmacol Ther. 2024. PMID: 39365028. doi:10.1002/cpt.3458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。